Inclusion Criteria:

          -  Male and female 18 years old and above

          -  Able to understand and sign informed consent form

          -  Patients with histologically or cytologically confirmed advanced solid tumors who have
             relapsed or refractory disease or relapsed/refractory AML for which no standard
             therapies expected to produce clinical benefit to the patient are available

          -  Patients with diagnosed solid tumors must have at least one lesion that is measurable
             per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria

          -  Patients with relapsed or refractory AML must be diagnosed with AML based on World
             Health Organization (WHO) criteria (≥ 20% blasts in bone marrow). Patients with acute
             promyelocytic leukemia are excluded

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

          -  Have discontinued all previous cancer therapies for at least 21 days or 5 half-lives
             prior to study treatment, whichever is shorter, and recovered from the acute adverse
             effects of therapy

          -  Expected to survive at least 2 to 3 months

          -  LVEF ≥ 50% and QTc interval < 450 ms

          -  Women shall meet either of the following conditions before enrollment

          -  Infertile, defined as having a bilateral oophorectomy (ovariectomy), or a bilateral
             tubal ligation, or being post-menopausal for at least 1 year.

          -  For those of childbearing potential, they should have a negative serum pregnancy test
             during screening, agree to refrain from lactation, and use effective contraception
             such as hormonal methods associated with inhibition of ovulation, condom,
             intra-uterine device, surgical sterilization (including partner's vasectomy) or sexual
             abstinence during the study and 30 days after the last administration of study drug.

          -  Men who are engaging or plan to engage in sexual activity with a female of
             childbearing potential must either have a prior vasectomy or agree to use effective
             contraception such as condoms, sexual abstinence and appropriate methods taken by
             their partner(s) during the study and 90 days after the last dose.

          -  Patients must have adequate organ functions as indicated by the following screening
             laboratory values:

          -  Serum total bilirubin ≤ 1.5 × upper limit normal (ULN) (Serum total bilirubin can be ≤
             3.0 × ULN if patients have hemolysis or congenital hemolytic diseases)

          -  Creatinine < 1.5 × ULN or estimated creatinine clearance ≥ 50 mL/min

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN or

               -  5 X ULN for patient with liver metastases

          -  Absolute neutrophil count (ANC) ≥ 1.5×10^9/L

          -  Platelets ≥ 100×10^9/L

          -  Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L (Note: Criteria must be met without a transfusion
             within 2 weeks of obtaining the sample) Note: Laboratory requirements for complete
             blood counts (hemoglobin, ANC, and platelets) do not apply to AML patients

        Exclusion Criteria:

          -  Participation in another therapeutic clinical trial within 3 weeks of enrollment

          -  A previous toxicity-related reaction towards cancer therapy have not recovered within
             2 weeks of enrollment (>Grade 2 National Cancer Institute-Common Terminology Criteria
             for Adverse Events (NCI CTCAE) Version 4.03)

          -  Having received a major surgical operation within 4 weeks of enrollment or not yet
             completely recovered from a previous operation

          -  Any serious or uncontrollable systemic disease, including but not limited to:
             Hypertension (after treatment, systolic blood pressure (SBP) > 180 mmHg and/or
             diastolic blood pressure (DBP) > 100 mmHg) and active hemorrhagic disorders; patients
             who are determined by investigators as otherwise not suitable for participation in
             this study.Note: Patients that in the judgment of the investigator have clinical signs
             of disease progression during the screening period (i.e.: febrile neutropenia, ascites
             requiring drainage, hospitalization due to worsening underlying disease, etc.) will
             not be eligible for participation.

          -  Active known infection, including hepatitis B, hepatitis C, and human immunodeficiency
             virus

          -  Primary central nervous system (CNS) tumor or CNS metastases, as indicated by clinical
             symptoms, cerebral edema, and/or progressive growth (patients with a history of CNS
             metastases or cord compression are allowable if they have been definitively treated
             and have been clinically stable for at least 3 months, and off steroids or
             anticonvulsants ≥ 2 weeks before first dose of study drug)

          -  Serious kidney injury, requiring dialysis

          -  Serious liver injury, and advanced liver diseases of Child-Pugh class B and C

          -  On medications that are strong cytochrome P450(CYP)3A inhibitors or inducers unless
             patients are willing and able to change to use of an equivalent medication that is not
             a strong CYP3A inhibitor or inducer

          -  Cardiac function and disease history which meets one or more of the following
             conditions:

          -  Any risk which may increase QTc interval prolongation, such as hypokalemia, hereditary
             long QT syndrome and taking drugs that can prolong QT interval

          -  Acute myocardial infarction ≤ 6 months prior to Day 1

          -  Clinically significant arrhythmia ≤ 6 months prior to Day 1

          -  Congestive heart failure ≥ Grade 3 by New York Heart Association (NYHA) ≤ 6 months
             prior to Day 1

          -  Cerebral vascular accident (CVA) ≤ 6 months prior to Day 1

          -  Are pregnant or breastfeeding